Shiyi has a number of innovative drugs in the United States to carry out clinical trials, butalbital soft capsule has been in the phase II clinical stage, butalbital, antibody drug coupling ADC (DP303c), humanized gap junction protein 43 monoclonal antibody (ALMB-0166), etc. have been issued by the U.S. FDA to qualify for orphan drug and to start the clinical trial of the new drug, have been Tramadol Hydrochloride Tablets, Benzonate Soft Capsules and other 16 varieties have been approved by ANDA, and 8 approved varieties have realized sales in the United States. In addition, Shiyi Group's hypertension treatment drug Levamlodipine Maleate has applied for NDA in the U.S., which is the first time for a Chinese pharmaceutical company to submit a new drug listing application to the U.S. FDA.

Shiyao Group has always been actively fulfilling its corporate social responsibility and is enthusiastic about public welfare. It has been involved in funding and rescue work in major diseases and natural disasters such as SARS, Indonesia tsunami, Wenchuan earthquake, Yushu earthquake, Ya'an earthquake, etc. It has also been actively involved in charitable and public welfare activities such as medical treatment for children with serious illnesses, volunteer services, and condolences to the old districts, etc., and spreads positive energy of public welfare with concrete actions.